drugset / Trial / NCT07540754

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

NCT07540754

Phase 1 Recruiting 24 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.

Timeline

Start
2026-05-26
Primary completion
2027-01
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown

Indications